Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.
Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.